EUCTR2015-000313-40-Outside-EU/EEA进行中（未招募）不适用
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents.
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- 12 years to < 18 years of age at Baseline
- •- Able to give written assent prior to any screening evaluations
- •- Parent or guardian able to give written informed consent prior to any screening evaluations and willing to comply with study requirements.
- •- Plasma HIV-1 RNA levels of = 1,000 copies/mL at screening (Roche COBAS TaqMan v2.0)
- •- CD4+ cell count > 100 cells/µL
- •- Weight = 35 kg (77 lbs)
- •- Screening genotype report provided by Gilead Sciences must show sensitivity to FTC and TDF using the GenoSure RT/PR assay
- •- Able to swallow oral tablets
- •- Adequate renal function: Estimated glomerular filtration rate = 90 mL/min/1.73m2 (using Schwartz Formula)
- •- Clinically normal ECG (or if abnormal, determined by the investigator to be not clinically significant)
- •- Documented screening for active pulmonary tuberculosis per local standard of care within 6 months of a screening visit
- •- Hepatic transaminases (AST and ALT) = 5 x upper limit of normal (ULN)
- •- Total bilirubin = 1.5 mg/dL, or normal direct bilirubin
- •- Subjects with a positive Hepatitis B surface antigen screening test can participate in the study, providing that alternate therapy (other than TDF) for chronic Hepatitis B infection is available to the subjects as a part of local standard of care
- •- Adequate hematologic function (absolute neutrophil count = 500/mm3; platelets = 50,000/mm3; hemoglobin = 8.5 g/dL)
- •- Negative serum pregnancy test for all female subjects
- •- Male and female subjects of childbearing potential must agree to utilize highly effective contraception methods while on study treatment or agree to abstain from heterosexual intercourse throughout the study period and for 30 days following the last dose of study drug. (Female subjects who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing. It is recommended that an oral contraceptive contain at least 30 µg of ethinyl estradiol if administered with EVG/COBI/FTC/TDF STR.)
- •- Male subjects must agree to utilize a highly effective method of contraception during heterosexual intercourse throughout the study period and for 30 days following discontinuation of investigational medicinal product
- •- Must be willing and able to comply with all study requirements
- •- Life expectancy = 1 year.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 50
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- A new AIDS-defining condition (CDC 1993 case definitions, with the exception of CD4+ cell count criteria) diagnosed within the 30 days prior to screening.
- •- Prior treatment with any approved or investigational or experimental anti HIV-1 drug for any length of time (other than that given for prevention of mother-to-child transmission)
- •- Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 months of the screening visit.
- •- Anticipated to require rifamycin treatment for mycobacterial infection while participating in the study. Note: prophylactic INH therapy for latent TB treatment is allowed.
- •- Subjects experiencing decompensated cirrhosis (e.g., ascites, encephalopathy, etc.)
- •- Pregnant or lactating subjects.
- •- Have any serious or active medical or psychiatric illness which, in the opinion of the Investigator, would interfere with subject treatment, assessment, or compliance with the protocol.
- •- Current alcohol or substance abuse judged by the Investigator to potentially interfere with subject compliance.
- •- Have history of significant drug sensitivity or drug allergy.
- •- Known hypersensitivity to the study drugs, the metabolites or formulation excipients
- •- Have been treated with immunosuppressant therapies or chemotherapeutic agents within 3 months of study screening or expected to receive these agents during the study
- •- A history of malignancy within the past 5 years (prior to screening) or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma. Subjects with cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of Baseline and must not be anticipated to require systemic therapy during the study.
- •- Have previously participated in an investigational trial involving administration of any investigational agent within 30 days prior to the study dosing.
- •- Participation in any other clinical trial without prior approval from sponsor is prohibited while participating in this trial.
- •- Subjects receiving ongoing therapy with any of the medications listed in the table within the exclusion criteria section of the protocol (Protocol Section 4.3), including drugs not to be used with EVG, COBI, FTC, TDF or subjects with any known allergies to the excipients of EVG/COBI/FTC/TDF STR tablets.
研究者
相似试验
进行中（未招募）
1 期
This study will test an experimental drug named GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) for the possible treatment of human immunodeficiency virus (HIV) infection in children and adolescents. The purpose of this study is to determine the concentration of GS-9883 in your child's body, and confirm the safety, tolerability and dose of GS-9883/F/TAF in HIV-1 infected adolescents (12 to < 18 years of age) and children (6 to <12 years of age).EUCTR2016-002345-39-Outside-EU/EEAGilead Sciences, Inc.
进行中（未招募）
1 期
A clinical study looking at the safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single tablet regimen (STR) in HIV-1 infected adolescents who have never previously been treated and in children who are currently receiving treatment.EUCTR2013-002780-26-Outside-EU/EEAGilead Sciences, Inc.100
撤回
1 期
A Phase 1b open label study of the pharmacokinetics and safety of oral OCX063 in adults with chronic kidney diseaseRenal and Urogenital - Kidney diseaseChronic kidney diseaseACTRN12623000732684OccuRx Pty Ltd12
尚未招募
不适用
A5375-A169 Respiratory tuberculosis unspecified, without mention of bacteriological or histological confirmation-B24 Unspecified human immunodeficiency virus [HIV] diseaseRespiratory tuberculosis unspecified, without mention of bacteriological or histological confirmationUnspecified human immunodeficiency virus [HIV] diseaseA169B24PER-024-19INSTITUTO NACIONAL DE ALERGIAS Y ENFERMEDADES INFECCIOSAS DE LOS ESTADOS UNIDOS,
进行中（未招募）
不适用
A study evaluating the Pharmacokinetics and Tolerability of Lu AA21004 in Child and Adolescent Patients With Depressive or Anxiety DisorderEUCTR2010-020170-42-DEH. Lundbeck A/S48